Novavax Stock News

Despite seemingly good news, shares of biotechnology firm Novavax (NASDAQ: NVAX ) suffered a significant decline. Earlier Friday morning, management announced the availability of its Covid-19 vaccine

Novavax said on Friday its updated COVID-19 vaccine was available across pharmacies in the United States.

Novavax missed out on a big opportunity for vaccine revenue -- but a new opportunity could be just ahead. Still, some uncertainty remains regarding the company's ability to turn things around and carv

Owing to the slow uptake of Novavax's (NVAX) COVID-19 vaccine, the company is trying to develop other vaccine candidates targeting different indications.

NVAX's H2'23 estimates appear to be overly bullish, based on PFE's pessimistic commentary with only 24% of the US population likely to be vaccinated with COVID vaccines in 2023. As a result of the pot

Vaccine maker Novavax Inc on Monday said it has shipped its updated COVID-19 shots to distributors after receiving the go-ahead from U.S. regulators.

Pharma stocks and the biotech sector can offer explosive gains. It also offers incredibly crushing defeats in which share prices decline precipitously.

Novavax's Covid shot is arriving nearly three weeks after new jabs from Pfizer and Moderna reached Americans — but analysts aren't worried about that delay.

Novavax is about to join Moderna and Pfizer in the fall vaccine marketplace. The company just won a nod from the FDA for its updated coronavirus vaccine shot, at a time when market demand is surpassin

Novavax's (NVAX) updated COVID vaccine is authorized under emergency use for individuals aged 12 years and older. It is currently the only non-mRNA COVID vaccine available in the country.

Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in

The Food and Drug Administration signed off on Novavax's updated Covid booster late Tuesday, and NVAX stock surged just before the close.

Novavax Inc.'s NVAX, +11.57% new COVID shot got a green light from the U.S. Food and Drug Administration Tuesday.

Shares were up more than 10% on the news, which came more than three weeks after vaccines from Moderna and Pfizer.

The U.S. Food and Drug Administration on Tuesday authorized an updated version of Novavax's protein-based COVID-19 vaccine for emergency use in individuals aged 12 years and older, the health regulato